microdroplet-based PCR

NEW YORK (GenomeWeb News) – Myriad Genetics will adopt RainDance Technologies' microdroplet PCR-based target enrichment technology for use in a next-generation sequencing-based hereditary cancer panel test that Myriad is currently developing, the companies said today.

NEW YORK (GenomeWeb News) – RainDance Technologies today said that it has completed a collaboration with MLL Munich Leukemia Laboratory on the development of a panel for use in the sequence-based analysis of acute myeloid leukemia and myelodysplastic syndromes.

SUNY researchers are developing a droplet microfluidics device to extract mRNA from single cells, creating cDNA libraries in individual droplets for gene expression analysis.

RainDance's Sequence Enrichment application enhances SeqWright's targeted resequencing and whole-genome sequencing capabilities for studying disease pathways, cancer, and other areas of research, SeqWright said.

Ambry Genetics, which has a CAP-accredited and CLIA-certified laboratory, is using RainDance's RDT 1000 for micro-droplet PCR-based enrichment of target DNA for sequencing.

Under the partnership, Ambry will incorporate RainDance's RDT 1000 platform into sequence enrichment and targeted resequencing applications.

The study, published in Nature Biotechnology, found that RainDance Technologies' microdroplet-based PCR technology was more scalable than standard PCR for sequence enrichment, with comparable sensitivity and accuracy.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.